Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 9;9:249. doi: 10.3389/fonc.2019.00249

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Huang, Wu, Sung, Liou, Lin, Pan and Yang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Combination treatment of MPT0G413 and bortezomib inhibited multiple myeloma cell growth and VEGF and IL-6 release. (A–C) RPMI-8226 and NCI-H929 multiple myeloma cells were co-cultured with or without HS-5 bone marrow stromal cells and subsequently treated with the indicated concentrations of MPT0G413, bortezomib, or both therapies for 48 h. Cell proliferation (A) was evaluated using a BrdU proliferation assay. VEGF (B) and IL-6 (C) levels were detected using respective ELISA kits. #p < 0.05, ##p < 0.01, and ###p < 0.001 compared with the untreated group (without HS-5). ^*p < 0.05, ^**p < 0.01, and ^***p < 0.001 compared with the untreated group (with HS-5) (n = 3).